Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells

Blood

Volumn 97, Issue 2, 2001, Pages 516-522

  Hjertner, Öyvind ^a   Hjorth Hansen, Henrik ^a   Börset, Magne ^a   Seidel, Carina ^a   Waage, Anders ^a   Sundan, Anders ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 4; RECOMBINANT INTERLEUKIN 6; RECOMBINANT PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RESPONSIVE ELEMENT; DNA SYNTHESIS INHIBITION; DOWN REGULATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INHIBITION KINETICS; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; TUMOR CELL LINE;

EID: 0035863916     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V97.2.516     Document Type: Article

References (60)

1. Multiple myeloma: Increasing evidence for a multistep transformation process
2. Growth control mechanisms in multiple myeloma
3. γ-Interferon in multiple myeloma: Inhibition of interleukin-6 (IL- 6)-dependent myeloma cell growth and down-regulation of IL-6-receptor expression in vitro
4. Recombinant interferon-γ inhibits the growth of IL-6-dependent human multiple myeloma cell lines in vitro
5. Should α-interferon be included as standard treatment in multiple myeloma?
6. Interferon alfa-2b versus no maintenance therapy during the plateau phase in multiple myeloma: A randomized study
7. Recombinant interferon gamma in hairy cell leukemia, multiple myeloma, and Waldenstrom's macroglobulinemia
8. The plasmacytoma growth inhibitor restrictin-P is an antagonist of interleukin 6 and interleukin 11: Identification as a stroma-derived activin A
9. Correlation between Bcl-X expression and B-cell hybridoma apoptosis induced by activin A
10. Activin A induces apoptotic cell death
11. Activin A induction of cell-cycle arrest involves modulation of cyclin D2 and p21ClP1/WAF1 in plasmacytic cells
12. Apoptosis, proliferation and NF-kB activation induced by agonistic Fas antibodies in the human myeloma cell line OH-2: Amplification of Fas-mediated apoptosis by tumor necrosis factor
13. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells
14. Bone: Formation by autoinduction
15. Biochemical sequences in the transformation of normal fibroblasts in adolescent rats
16. Bone morphogenetic proteins: From basic studies to clinical approaches
17. Localization of Smads, the TGF-β family intracellular signaling components during endochondral ossification
18. Bone and cartilage differentiation
19. Differentiation of human marrow stromal precursor cells: Bone morphogenetic protein-2 increases OSF2/CBFA1, enhances osteoblast commitment, and inhibits late adipocyte maturation
20. Essential requirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: Antagonism by noggin
21. Growth factors for bone growth and repair: IGF, TGF beta and BMP
22. Retinoic acid regulates programmed cell death through BMP signalling
23. The signalling molecule BMP4 mediates apoptosis in the rhombencephalic neural crest
24. Experimental induction of BMP-4 expression leads to apoptosis in the paraxial and lateral plate mesoderm
25. Growth regulation of human prostate cancer cells by bone morphogenetic protein-2
26. Antiproliferative effects of recombinant human bone morphogenetic protein-2 on human tumor colony-forming units
27. Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo
28. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells
29. Immunolocalization and messenger RNA expression of bone morphogenetic protein-6 in human benign and malignant prostatic tissue
30. Transcriptional regulation of blood formation during Xenopus development
31. Periosteal and intratumorous bone formation in athymic nude mice by Chinese hamster ovary tumors expressing murine bone morphogenetic protein-4
32. Development of hemopoietic bone marrow within the ectopic bone induced by bone morphogenetic protein
33. Lineage-restricted expression of bone morphogenetic protein genes in human hematopoietic cell lines
34. Bone morphogenetic protein 9 is a potent synergistic factor for murine hemopoietic progenitor cell generation and colony formation in serum-free cultures
35. Bone morphogenetic proteins regulate the developmental program of human hematopoietic stem cells
36. TNF and IL-6 are potent growth factors for OH-2, a novel human myeloma cell line
37. Lack of IL-1 secretion from human myeloma cells highly purified by immunomagnetic separation
38. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells
39. IL-6 triggers cell growth via the Ras-dependent mitogen-activated protein kinase cascade
40. STATs and gene regulation
41. TGF-beta signalling from cell membrane to nucleus through SMAD proteins
42. Smads: Transcriptional activators of TGF-beta responses
43. Roles of protein phosphatase 1 and 2A in an IL-6-mediated autocrine growth loop of human myeloma cells
44. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL
45. Expression of Apo-1/Fas (CD95), Bcl-2, Bax and Bcl-x in myeloma cell lines: Relationship between responsiveness to anti-Fas mab and p53 functional status
46. Bcl-2 initiates a new category of oncogenes: Regulators of cell death
47. Differential inhibition of Smad6 and Smad7 on bone morphogenetic protein- and activin-mediated growth arrest and apoptosis in B cells
48. Specific activation of the p38 mitogen-activated protein kinase signaling pathway and induction of neurite outgrowth in PC12 cells by bone morphogenetic protein-2
49. Protein kinase A is a negative regulator of renal branching morphogenesis and modulates inhibitory and stimulatory bone morphogenetic proteins
50. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction
51. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells
52. Interleukin-6 overcomes p21WAF1 up-regulation and G1 growth arrest induced by dexamethasone and interferon-γ in multiple myeloma cells
53. Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-gamma and interf
54. Expression of Fas/Apo-1 (CD95) and apoptosis in tumor cells from patients with plasma cell disorders
55. Interleukin-6 inhibits apoptosis of malignant plasma cells
56. Interferon-beta interrupts interleukin-6-dependent signaling events in myeloma cells
57. Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines
58. Evidence for the up-regulation of osteogenic protein-1 mRNA expression in musculo-skeletal neoplasms
59. Expression of bone morphogenetic protein 6 in normal mammary tissue and breast cancer cell lines and its regulation by epidermal growth factor
60. A clinical staging system for multiple myeloma: Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival